Global X S&P Biotech ETF (ASX:CURE)

Assets	48.31M
Expense Ratio	0.45%
PE Ratio	n/a
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+58.43%

Volume	1,728
Open	76.90
Previous Close	75.92
Day's Range	76.90 - 77.87
52-Week Low	49.59
52-Week High	81.49
Beta	0.33
Holdings	10
Inception Date	Nov 8, 2018

About CURE

The Global X S&P Biotech ETF, identified by its ticker CURE, endeavors to replicate the overall financial performance, encompassing both capital gains and dividends, of the S&P Biotechnology Select Industry Index, before any management fees and operational costs are deducted.

• Asset Class: Equity
• Category: Health Care
• Region: North America
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CURE
• Provider: Global X
• Index Tracked: S&P Biotechnology Select Industry

Performance

CURE had a total return of 58.43% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.22%.

Top Holdings

15.66% of assets

Name	Symbol	Weight
Twist Bioscience Corporation	TWST	1.92%
Moderna, Inc.	MRNA	1.64%
Natera, Inc.	NTRA	1.61%
AbbVie Inc.	ABBV	1.52%
Halozyme Therapeutics, Inc.	HALO	1.51%
TG Therapeutics, Inc.	TGTX	1.50%
CRISPR Therapeutics AG	CRSP	1.50%
Spyre Therapeutics, Inc.	SYRE	1.50%
Oruka Therapeutics, Inc.	ORKA	1.49%
Gilead Sciences, Inc.	GILD	1.48%

Data Sources: S&P Global Market Intelligence, Financial Modeling Prep, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error